STK11 and cancer: Interestingly, while mSTK11-KEAP1 WT was also more prevalent in patients with KRAS G12C-positive cancer vs KRAS WT cancer (13.0% vs 9.0%; p = 0.05), STK11 WT-mKEAP1 was more prevalent in patients with KRAS WT cancer vs KRAS G12C-positive cancer (15.0% vs 7.0%; p < 0.001) (Table 1).